{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:29Z","timestamp":1790790209833,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12265-019-09895-0","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T15:02:58Z","timestamp":1560870178000},"page":"507-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome"],"prefix":"10.1007","volume":"12","author":[{"given":"Isabel","family":"Zegri-Reiriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"de Haro-del Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"de la Cuadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aresio","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Krsnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"9895_CR1","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. (2015). Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal, 36, 2585\u20132594.","journal-title":"European Heart Journal"},{"key":"9895_CR2","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer, M. S., Elliot, P., Comenzo, R., et al. (2017). Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis. Circulation, 135, 1357\u20131377.","journal-title":"Circulation"},{"key":"9895_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho, T., Maia, L. F., Martins da Silva, A., et al. (2012). Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology, 79, 785\u2013792.","journal-title":"Neurology"},{"key":"9895_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/13506129.2012.673140","volume":"19","author":"EJ Ackermann","year":"2012","unstructured":"Ackermann, E. J., Guo, S., Booten, S., et al. (2012). Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid, 19, 43\u201344.","journal-title":"Amyloid"},{"key":"9895_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.recesp.2017.05.018","volume":"70","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez, E., L\u00f3pez-Sainz, \u00c1., & Garcia-Pavia, P. (2017). Diagnosis and treatment of Transthyretin cardiac amyloidosis. Progress and hope. Revista Espa\u00f1ola de Cardiolog\u00eda, 70, 991\u20131004.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"9895_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi, C., Merlini, G., Quarta, C. C., et al. (2009). Systemic cardiac amyloidosis: disease profiles and clinical courses of the 3 main types. Circulation, 120, 1203\u20131212.","journal-title":"Circulation"},{"key":"9895_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","volume":"23","author":"M Nakagawa","year":"2016","unstructured":"Nakagawa, M., Sekijima, Y., Yazaki, M., et al. (2016). Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid, 23, 58\u201363.","journal-title":"Amyloid"},{"key":"9895_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/13506120209114102","volume":"9","author":"Y Takei","year":"2002","unstructured":"Takei, Y., Hattori, T., Gono, T., et al. (2002). Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid, 9, 252\u2013255.","journal-title":"Amyloid"},{"key":"9895_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore, J. D., Maurer, M. S., Falk, R. H., et al. (2016). Non-biopsy diagnosis of cardiac Transthyretin amyloidosis. Circulation, 133, 2404\u20132412.","journal-title":"Circulation"},{"key":"9895_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.recesp.2011.12.015","volume":"65","author":"FJ de Haro-del Moral","year":"2012","unstructured":"de Haro-del Moral, F. J., Sanchez-Lajusticia, A., Gomez-Bueno, M., Garcia-Pavia, P., Salas-Anton, C., & Segovia-Cubero, J. (2012). Role of cardiac scintigraphy with (9)(9)mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol, 65, 440\u2013446.","journal-title":"Rev Esp Cardiol"},{"key":"9895_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada, I., Comenzo, R. L., Landau, H., et al. (2015). Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Advances in Therapy, 32, 920\u2013928.","journal-title":"Advances in Therapy"},{"key":"9895_CR12","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez, E., Gagliardi, C., Dominguez, F., et al. (2017). Clinical characteristics of wild-type transthyretin cardiac amyloidosis \u2013 disproving myths. European Heart Journal, 38, 1895\u20131904.","journal-title":"European Heart Journal"},{"key":"9895_CR13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","volume":"42","author":"Y Sekijima","year":"2011","unstructured":"Sekijima, Y., Uchiyama, S., Tojo, K., et al. (2011). High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Human Pathology, 42, 1785\u20131791.","journal-title":"Human Pathology"},{"key":"9895_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller, H. I., Singh, A., Alexander, K. M., et al. (2017). Association between ruptured distal biceps tendon and wild-type Transthyretin cardiac amyloidosis. JAMA, 318, 962\u2013963.","journal-title":"JAMA"},{"key":"9895_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","volume":"84","author":"JP Donnelly","year":"2017","unstructured":"Donnelly, J. P., & Hanna, M. (2017). Cardiac amyloidosis: an update on diagnosis and treatment. Cleveland Clinic Journal of Medicine, 84, 12\u201326.","journal-title":"Cleveland Clinic Journal of Medicine"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-019-09895-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:22:54Z","timestamp":1592349774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-019-09895-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9895"],"URL":"https:\/\/doi.org\/10.1007\/s12265-019-09895-0","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"15 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EGL reports consulting and speaking fees from Pfizer. PGP reports consulting fees from Akcea, Alnylam, Eidos, Neuroinmmune, Pfizer and Prothena; speaking fees from Akcea, Alnylam, Eidos, Pfizer and Prothena; and research funding from Alnylam, Pfizer and Prothena. Other authors have no conflict of interest relevant to this work to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}